Abstract:Purpose: We aimed to compare the relative diagnostic efficacy of 68 Ga-Labeled DOTA-ibandronic acid ( 68 Ga-DOTA-IBA) to that of 18 F-NaF PET/CT as a mean of detecting bone metastases in patients with a range of cancer types Methods: This study retrospectively enrolled patients with bone metastases associated with various underlying malignancies. All patients underwent both 68 Ga-DOTA-IBA and 18 F-NaF PET/CT scans. Histopathology and follow-up CT or MRI imaging results were used as reference criteria, with a minimum follow-up period of 3 months. The maximum Standardized Uptake Value (SUVmax) and number of bone metastases were recorded. The Target-Background Ratio (TBR) was calculated along with the detection rate, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of 68 Ga-DOTA-IBA and 18 F-NaF PET/CT imaging for overall and partial primary solid tumor bone metastases. Pearson chi-square test, McNemar test, and Kappa test was conducted to assess the correlation and consistency of diagnostic efficiency between the two imaging agents. Receiver Operating Characteristic curve (ROC curve) was performed to compare diagnostic performance and the area under the curve of the two imaging agents, determining optimal critical values for SUVmax and TBR in diagnosing bone metastasis. Differences in SUVmax and TBR values between the two imaging agents for detecting bone metastases were analyzed using the Wilcoxon signed rank test. The difference was statistically significant when P < 0.05 Results: A total of 24 patients (13 women and 11 men) were included in this study, with a mean age of 52 (interquartile range, 49-64 years). The detection rate, sensitivity, specificity, PPV, NPV, accuracy, and AUC of 68 Ga-DOTA-IBA and 18 F-NaF PET/CT for bone metastases were 81%, 90%, 62%, 95%, 43%, 88%, 0.763, and 89%, 99%, 59%, 95%, 89%, 95%, 0.789, respectively. There was no significant difference between the two imaging methods (P < 0.01), and there was a significant correlation (X 2 =168.43, P < 0.001) and a strong consistency (Kappa=0.774,P < 0.001) between the diagnostic results of the two imaging agents. The SUVmax values of lesions measured by 68 Ga-DOTA-IBA and 18 F-NaF imaging in 22 patients with bone metastasis were 5.1 ± 5.4 and 19.6 ± 15.1, respectively, with statistically significant differences (P<0.05). The TBR values of the two imaging methods were 5.0 ± 5.0 and 6.7 ± 6.4, respectively, with statistically significant differences (P<0.05). The AUC of the SUVmax of 68 Ga-DOTA-IBA and 18 F-NaF curves were 0.824 and 0.862, respectively, with no statistically significant difference (P=0.490). No significant difference was found in the AUC of the TBR of 68 Ga-DOTA-IBA and 18 F-NaF (0.832 vs 0.890; P=0.248). Subgroup analysis showed significant correlation between the two imaging agents in the diagnosis of bone metastases in lung cancer and breast cancer, with consistent diagnostic results. However, in the diagnosis of bone metastases in prostate cancer, there was a significant difference (P<0.001) and lack of consistency (P=0.109) Conclusion: The diagnostic efficacy of 68 Ga-DOTA-IBA for bone metastasis lesions is comparable to that of 18 F-NaF. This finding holds significant clinical importance in terms of diagnosis of bone metastasis and selecting treatment plans for patients with malignant tumors

Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies

Sodium Pump Na Plus /K Plus ATPase Subunit 1-Targeted Positron Emission Tomography Imaging of Hepatocellular Carcinoma in Mouse Models

Comparison of Cell Proliferation, Protein, and Glucose Metabolism in Musculoskeletal Tumors in a PET Study.

A Meta-Analysis on the Diagnostic Performance of (18)F-FDG and (11)C-Methionine PET for Differentiating Brain Tumors.

Imaging a Pancreatic Carcinoma Xenograft Model with 11C-Acetate: a Comparison Study with 18F-FDG

68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer

Potential utility of [68Ga]DOTA-FAPI-04 as a broad-spectrum benign disease imaging agent—comparison with [18F]FDG and [99mTc]MDP

[11C]Methionine PET vs. [18F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients

Usefulness of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT in Patients Presenting with Inconclusive [ 18 F]FDG PET/CT Findings

Comparison of the relative diagnostic performance of 68Ga-DOTA-IBA and 18F-NaF for the detection of bone metastasis

Initial clinical experience using 68Ga-FAPI-46 PET/CT for detecting various cancer types

Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors

Value of Dual-Phase ~(18)F-FDG PET in Diagnosis of Tumor

The Diagnosis of 18 F-fluorodexoxyglucose and 11C-Acetate PET/CT Scanning in Primary Liver Tumors and Tumor-Like Diseases : a Preliminary Study

Comparative Study of Metabolic Tumor Volume in Multiple Myeloma and Related Plasma Cell Dyscrasias: 11C-Acetate PET vs. 18F-FDG PET

Quantitative parameters of static imaging and fast kinetics imaging in <SUP>18</SUP>F-FDG total-body PET/CT for the assessment of histological feature of pulmonary lesions

Comparative Study of [18F]alf-Lnc1007, [18F]FDG, and [18F]alf-Nota-fapi-04 PET/CT in Breast Cancer Diagnosis: A Methodological Exploration and Analytical Insight

The role of [99mTc]Tc-HFAPi SPECT/CT in patients with malignancies of digestive system: first clinical experience

Superiority of [68Ga]ga-Dota-fapi-04 PET/CT to [18F]FDG PET/CT in the Evaluation of Thymic Epithelial Tumours.

Value of Semi-Quantitative Parameters of 68Ga-FAPI-04 PET/CT in Primary Malignant and Benign Diseases: A Comparison with 18F-FDG

The role of [ 99m Tc]Tc-HFAPi SPECT/CT in patients with malignancies of digestive system: first clinical experience